Cartesian Therapeutics Financials

RNAC Stock

7.42 0.06 0.82%

Based on the key indicators related to Cartesian Therapeutics' liquidity, profitability, solvency, and operating efficiency, Cartesian Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At present, Cartesian Therapeutics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 38.1 M, whereas Other Current Liabilities is forecasted to decline to about 15.5 M.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Cartesian Therapeutics Balance Sheet Chart

At present, Cartesian Therapeutics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 38.1 M, whereas Other Current Liabilities is forecasted to decline to about 15.5 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Key indicators impacting Cartesian Therapeutics' financial strength include:

Current Value

Last Year

Change From Last Year

10 Year Trend

Current Ratio

8.91

8.49

Sufficiently Up

Slightly volatile

The essential information of the day-to-day investment outlook for Cartesian Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Cartesian Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Cartesian Therapeutics.

Cash And Equivalents

96.76 Million

Build AI portfolio with Cartesian Stock

Please note, the presentation of Cartesian Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cartesian Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cartesian Therapeutics' management manipulating its earnings.

Cartesian Therapeutics Stock Summary

Cartesian Therapeutics competes with Inventiva, Nautilus Biotechnology, Orchestra BioMed, Mediwound, and Aardvark Therapeutics. Cartesian Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.

Specialization	Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Instrument	USA Stock View All
Exchange	NASDAQ Exchange
ISIN	US8162121045
Business Address	7495 New Horizon
Sector	Biotechnology
Industry	Health Care
Benchmark	Dow Jones Industrial
Website	www.cartesiantherapeutics.com
Phone	301 348 8698

Cartesian Therapeutics Key Financial Ratios

	Return On Equity	-70.29
	Operating Margin	(46.61) %
	Price To Sales	176.85 X
	Revenue	38.91 M
	Gross Profit	(51.76 M)

More Fundamentals

Cartesian Therapeutics Key Balance Sheet Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	159.9M	165.9M	305.1M	435.0M	500.3M	525.3M
Other Current Liab	10.5M	14.1M	60.6M	19.8M	22.8M	15.5M
Net Tangible Assets	8.4M	(18.0M)	22.5M	93.8M	107.9M	113.3M
Net Debt	(78.8M)	(68.5M)	(66.0M)	(198.6M)	(178.8M)	(169.8M)
Retained Earnings	(430.3M)	(394.9M)	(614.6M)	(692.1M)	(622.9M)	(591.7M)
Accounts Payable	224K	316K	3.2M	288K	259.2K	246.2K
Cash	114.1M	106.4M	76.9M	212.6M	244.5M	256.7M
Other Assets	1.4M	12.7M	159.9K	1.3M	1.5M	2.3M
Net Receivables	9.9M	9.9M	8.9M	872K	1.0M	952.7K
Other Current Assets	6.5M	3.7M	5.0M	3.1M	3.6M	4.0M
Total Liab	137.4M	72.1M	745.2M	441.8M	508.1M	533.5M
Total Current Assets	144.4M	148.1M	90.7M	216.6M	249.1M	261.6M
Short Term Debt	7.0M	10.1M	2.2M	2.9M	3.3M	3.1M
Common Stock	11K	12K	15K	16K	3.5K	3.3K
Capital Surpluse	348.7M	391.2M	457.4M	493.3M	567.3M	385.7M

Cartesian Therapeutics Key Income Statement Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Interest Expense	1.5M	1.6M	2.8M	3.0M	2.8M	0.0
Total Revenue	85.1M	110.8M	26.0M	38.9M	44.7M	30.2M
Gross Profit	85.1M	108.7M	26.0M	38.9M	44.7M	30.0M
Operating Income	(4.6M)	14.5M	(86.4M)	(43.9M)	(39.5M)	(41.5M)
Ebit	(6.9M)	37.8M	(235.9M)	(77.1M)	(69.4M)	(72.9M)
Research Development	68.7M	72.4M	71.3M	45.1M	51.9M	51.1M
Ebitda	(5.2M)	39.8M	(235.0M)	(76.0M)	(68.4M)	(71.8M)
Income Before Tax	(9.7M)	34.8M	(238.7M)	(77.1M)	(69.4M)	(72.9M)
Net Income	(25.7M)	35.4M	(219.7M)	(77.4M)	(69.7M)	(73.2M)
Income Tax Expense	16.0M	(609K)	(19M)	287K	258.3K	169.7K
Interest Income	2.8M	980K	5.0M	7.4M	8.5M	8.9M
Net Interest Income	(2.8M)	(3.0M)	(2.8M)	7.4M	8.5M	8.9M
Tax Provision	16.0M	(609K)	(19M)	287K	258.3K	271.2K

Cartesian Therapeutics Key Cash Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Change To Inventory	(7.2M)	211K	920K	(3.8M)	(3.5M)	(3.3M)
Investments	(16.1M)	(13.8M)	34.6M	(8.7M)	(10.1M)	(9.6M)
Change In Cash	(24.6M)	(7.4M)	(29.8M)	136.0M	156.4M	164.2M
Free Cash Flow	(61.5M)	(32.8M)	(51.4M)	(32.8M)	(29.5M)	(31.0M)
Depreciation	1.3M	1.3M	843K	1.2M	1.3M	1.2M
Other Non Cash Items	2.1M	2.3M	159.2M	51.5M	59.2M	62.2M
Capital Expenditures	1.1M	1.2M	206K	9.1M	10.5M	11.0M
Net Income	(25.7M)	35.4M	(219.7M)	(77.4M)	(69.7M)	(73.2M)
End Period Cash Flow	115.4M	108.0M	78.3M	214.3M	246.4M	258.7M
Change To Netincome	6.4M	16.9M	11.1M	(8.9M)	(10.2M)	(9.7M)

Cartesian Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cartesian Therapeutics's current stock value. Our valuation model uses many indicators to compare Cartesian Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cartesian Therapeutics competition to find correlations between indicators driving Cartesian Therapeutics's intrinsic value. More Info.

Cartesian Therapeutics is rated below average in return on equity category among its peers. It is rated third in return on asset category among its peers . At present, Cartesian Therapeutics' Return On Equity is projected to increase based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cartesian Therapeutics' earnings, one of the primary drivers of an investment's value.

Most indicators from Cartesian Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cartesian Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Cartesian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.At present, Cartesian Therapeutics' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.42, whereas Selling General Administrative is forecasted to decline to about 21.7 M.

	2023	2024	2025	2026 (projected)
Gross Profit	26.0M	38.9M	44.7M	30.0M
Total Revenue	26.0M	38.9M	44.7M	30.2M

Gross Profit Total Revenue

Cartesian Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab
Total Assets		0.23	0.57	0.36	0.0	0.54	0.81	0.9	0.01	-0.94	-0.91	-0.11	0.95	0.95	0.57	0.11	0.52	0.93	0.08	0.9	-0.22	0.82	0.41	0.89	0.83	-0.23
Short Long Term Debt Total	0.23		0.05	0.64	0.49	0.68	0.44	0.51	0.61	-0.36	-0.43	-0.2	0.43	-0.02	0.1	0.4	0.61	0.48	0.72	0.09	0.4	-0.16	0.71	0.55	-0.08	-0.11
Other Current Liab	0.57	0.05		0.53	-0.63	0.46	0.63	0.53	-0.08	-0.4	-0.72	0.31	0.36	0.67	0.24	-0.03	0.39	0.34	0.47	0.28	-0.2	0.79	0.46	0.34	0.82	-0.23
Total Current Liabilities	0.36	0.64	0.53		-0.19	0.77	0.41	0.54	0.75	-0.38	-0.61	0.01	0.4	0.26	0.21	0.54	0.58	0.38	0.79	0.07	-0.14	0.3	0.83	0.41	0.4	-0.35
Total Stockholder Equity	0.0	0.49	-0.63	-0.19		0.15	0.17	0.05	0.13	-0.22	0.05	-0.34	0.26	-0.26	-0.13	0.0	0.15	0.33	-0.11	0.07	0.5	-0.56	0.02	0.4	-0.56	0.28
Other Liab	0.54	0.68	0.46	0.77	0.15		0.62	0.64	0.53	-0.67	-0.75	-0.13	0.66	0.37	0.44	0.55	0.87	0.66	0.62	0.29	-0.05	0.29	0.57	0.68	0.36	-0.27
Net Tangible Assets	0.81	0.44	0.63	0.41	0.17	0.62		0.76	-0.03	-0.78	-0.85	0.16	0.78	0.7	0.17	-0.06	0.59	0.83	0.33	0.55	0.27	0.55	0.55	0.84	0.57	0.09
Property Plant And Equipment Net	0.9	0.51	0.53	0.54	0.05	0.64	0.76		0.28	-0.87	-0.9	-0.23	0.9	0.8	0.61	0.29	0.57	0.89	0.39	0.75	-0.09	0.68	0.6	0.86	0.72	-0.39
Current Deferred Revenue	0.01	0.61	-0.08	0.75	0.13	0.53	-0.03	0.28		-0.16	-0.17	-0.21	0.18	-0.16	0.22	0.72	0.42	0.17	0.51	-0.13	-0.02	-0.16	0.63	0.16	-0.07	-0.19
Net Debt	-0.94	-0.36	-0.4	-0.38	-0.22	-0.67	-0.78	-0.87	-0.16		0.9	0.2	-0.98	-0.82	-0.62	-0.23	-0.64	-0.97	-0.08	-0.85	0.16	-0.64	-0.4	-0.93	-0.66	0.2
Retained Earnings	-0.91	-0.43	-0.72	-0.61	0.05	-0.75	-0.85	-0.9	-0.17	0.9		0.07	-0.88	-0.84	-0.52	-0.17	-0.66	-0.86	-0.41	-0.71	0.17	-0.74	-0.61	-0.87	-0.78	0.33
Accounts Payable	-0.11	-0.2	0.31	0.01	-0.34	-0.13	0.16	-0.23	-0.21	0.2	0.07		-0.24	-0.03	-0.34	-0.18	-0.05	-0.19	-0.01	-0.18	0.35	0.1	0.03	-0.25	0.1	0.56
Cash	0.95	0.43	0.36	0.4	0.26	0.66	0.78	0.9	0.18	-0.98	-0.88	-0.24		0.81	0.58	0.24	0.63	0.99	0.11	0.86	-0.13	0.62	0.44	0.96	0.64	-0.21
Non Current Assets Total	0.95	-0.02	0.67	0.26	-0.26	0.37	0.7	0.8	-0.16	-0.82	-0.84	-0.03	0.81		0.54	0.0	0.35	0.77	-0.02	0.87	-0.37	0.94	0.29	0.72	0.93	-0.28
Non Currrent Assets Other	0.57	0.1	0.24	0.21	-0.13	0.44	0.17	0.61	0.22	-0.62	-0.52	-0.34	0.58	0.54		0.34	0.5	0.53	0.08	0.65	-0.41	0.54	0.01	0.43	0.54	-0.54
Other Assets	0.11	0.4	-0.03	0.54	0.0	0.55	-0.06	0.29	0.72	-0.23	-0.17	-0.18	0.24	0.0	0.34		0.4	0.21	0.25	0.04	-0.26	0.03	0.29	0.14	0.09	-0.25
Long Term Debt	0.52	0.61	0.39	0.58	0.15	0.87	0.59	0.57	0.42	-0.64	-0.66	-0.05	0.63	0.35	0.5	0.4		0.65	0.45	0.34	0.16	0.29	0.46	0.61	0.35	0.01
Cash And Short Term Investments	0.93	0.48	0.34	0.38	0.33	0.66	0.83	0.89	0.17	-0.97	-0.86	-0.19	0.99	0.77	0.53	0.21	0.65		0.13	0.83	0.0	0.57	0.47	0.97	0.58	-0.12
Net Receivables	0.08	0.72	0.47	0.79	-0.11	0.62	0.33	0.39	0.51	-0.08	-0.41	-0.01	0.11	-0.02	0.08	0.25	0.45	0.13		-0.2	0.17	0.03	0.68	0.22	0.12	-0.39
Common Stock Shares Outstanding	0.9	0.09	0.28	0.07	0.07	0.29	0.55	0.75	-0.13	-0.85	-0.71	-0.18	0.86	0.87	0.65	0.04	0.34	0.83	-0.2		-0.32	0.72	0.14	0.77	0.7	-0.27
Short Term Investments	-0.22	0.4	-0.2	-0.14	0.5	-0.05	0.27	-0.09	-0.02	0.16	0.17	0.35	-0.13	-0.37	-0.41	-0.26	0.16	0.0	0.17	-0.32		-0.46	0.16	0.01	-0.46	0.68
Non Current Liabilities Total	0.82	-0.16	0.79	0.3	-0.56	0.29	0.55	0.68	-0.16	-0.64	-0.74	0.1	0.62	0.94	0.54	0.03	0.29	0.57	0.03	0.72	-0.46		0.24	0.48	0.99	-0.32
Other Current Assets	0.41	0.71	0.46	0.83	0.02	0.57	0.55	0.6	0.63	-0.4	-0.61	0.03	0.44	0.29	0.01	0.29	0.46	0.47	0.68	0.14	0.16	0.24		0.52	0.32	-0.08
Other Stockholder Equity	0.89	0.55	0.34	0.41	0.4	0.68	0.84	0.86	0.16	-0.93	-0.87	-0.25	0.96	0.72	0.43	0.14	0.61	0.97	0.22	0.77	0.01	0.48	0.52		0.51	-0.18
Total Liab	0.83	-0.08	0.82	0.4	-0.56	0.36	0.57	0.72	-0.07	-0.66	-0.78	0.1	0.64	0.93	0.54	0.09	0.35	0.58	0.12	0.7	-0.46	0.99	0.32	0.51		-0.35
Deferred Long Term Liab	-0.23	-0.11	-0.23	-0.35	0.28	-0.27	0.09	-0.39	-0.19	0.2	0.33	0.56	-0.21	-0.28	-0.54	-0.25	0.01	-0.12	-0.39	-0.27	0.68	-0.32	-0.08	-0.18	-0.35

Click cells to compare fundamentals

Cartesian Therapeutics Account Relationship Matchups

Cartesian Therapeutics fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	159.9M	165.9M	305.1M	435.0M	500.3M	525.3M
Other Current Liab	10.5M	14.1M	60.6M	19.8M	22.8M	15.5M
Net Tangible Assets	8.4M	(18.0M)	22.5M	93.8M	107.9M	113.3M
Net Debt	(78.8M)	(68.5M)	(66.0M)	(198.6M)	(178.8M)	(169.8M)
Retained Earnings	(430.3M)	(394.9M)	(614.6M)	(692.1M)	(622.9M)	(591.7M)
Accounts Payable	224K	316K	3.2M	288K	259.2K	246.2K
Cash	114.1M	106.4M	76.9M	212.6M	244.5M	256.7M
Other Assets	1.4M	12.7M	159.9K	1.3M	1.5M	2.3M
Net Receivables	9.9M	9.9M	8.9M	872K	1.0M	952.7K
Other Current Assets	6.5M	3.7M	5.0M	3.1M	3.6M	4.0M
Total Liab	137.4M	72.1M	745.2M	441.8M	508.1M	533.5M
Total Current Assets	144.4M	148.1M	90.7M	216.6M	249.1M	261.6M
Short Term Debt	7.0M	10.1M	2.2M	2.9M	3.3M	3.1M
Common Stock	11K	12K	15K	16K	3.5K	3.3K
Capital Surpluse	348.7M	391.2M	457.4M	493.3M	567.3M	385.7M

Today, most investors in Cartesian Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cartesian Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cartesian Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0481

At present, Cartesian Therapeutics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Cartesian Therapeutics January 17, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Cartesian Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cartesian Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cartesian Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Cartesian Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cartesian Therapeutics's daily price indicators and compare them against related drivers.

	Information Ratio	(0.07)
	Maximum Drawdown	28.9
	Value At Risk	(8.01)
	Potential Upside	7.64

Complementary Tools for Cartesian Stock analysis

When running Cartesian Therapeutics' price analysis, check to measure Cartesian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cartesian Therapeutics is operating at the current time. Most of Cartesian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cartesian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cartesian Therapeutics' price. Additionally, you may evaluate how the addition of Cartesian Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Cartesian Therapeutics Financials

Cartesian Therapeutics Balance Sheet Chart

Cash And Equivalents

96.76 Million

Cartesian Therapeutics Stock Summary

Cartesian Therapeutics Key Financial Ratios

Cartesian Therapeutics Key Balance Sheet Accounts

Cartesian Therapeutics Key Income Statement Accounts

Cartesian Therapeutics Key Cash Accounts

Cartesian Financial Ratios Relationships

Cartesian Therapeutics fundamental ratios Correlations

Cartesian Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cartesian Therapeutics fundamental ratios Accounts

Price Earnings To Growth Ratio

0.0481

Cartesian Therapeutics January 17, 2026 Opportunity Range

Complementary Tools for Cartesian Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 0.99	Cash
Total Liab	+ 0.99	Non Current Liabilities Total
Other Stockholder Equity	+ 0.97	Cash And Short Term Investments
Other Stockholder Equity	+ 0.96	Cash
Cash	+ 0.95	Total Assets
Non Current Assets Total	+ 0.95	Total Assets

Cash	- 0.98	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Net Debt	- 0.94	Total Assets
Other Stockholder Equity	- 0.93	Net Debt
Retained Earnings	- 0.91	Total Assets
Retained Earnings	- 0.9	Property Plant And Equipment Net